MedPath

Investigating the Effect of Dietary Supplement VSL#3 on Cognition and Mood in Healthy Older Adults

Not Applicable
Conditions
Alteration of Cognitive Function
Disturbance in Affect (Finding)
Interventions
Dietary Supplement: placebo
Dietary Supplement: VSL#3
Registration Number
NCT01877967
Lead Sponsor
University of Dublin, Trinity College
Brief Summary

This research aims to determine whether a 12 week daily dose of VSL#3 has any measurable effects on memory, attention, executive function or self-reported mood and anxiety in healthy older adults.

Detailed Description

This research aims to investigate the effect of dietary supplement VSL#3 on memory, attention, executive function and mood in healthy older adults.

The study will be a randomised double-blind placebo-controlled design and eighty participants will be recruited to take part. Forty participants will be randomly allocated to the food supplement and 40 to placebo. As the sample is initially self-selecting where individuals volunteer to take part, a minimisation procedure will be used to randomise group allocation (Altman \& Bland, 2005), with volunteers stratified by gender. Neither the participant nor the research assistant supplying the supplement will know which preparation is administered, thus ensuring double-blind administration.

Participants will be asked to take the food supplement daily for 12 weeks and the pre- and post- intervention data will be collected immediately before and after this time period.

Both pre- and post-intervention data will be collected using validated neuropsychological measures, cognitive measures, EEG and self-report questionnaires. Blood sampling will be conducted pre- and post-intervention by a Research Assistant trained in phlebotomy. Analysis will be carried out on each of the measures using a two-way ANCOVA, using the pre-treatment score as covariate.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Aged between 65 and 75
  • MMSE score > 23
  • Willingness to give informed consent
  • Commitment to take the VSL#3 supplement daily for 12 weeks
  • Alcohol consumption less than 21 units per week (men), 14 units per week (women)
Read More
Exclusion Criteria
  • Current psychoactive medication
  • Significant active medical conditions
  • History of major psychiatric or neurological condition
  • Smoker
  • History of epilepsy
  • History of traumatic brain injury
  • History of immunodeficiency
  • Taking immunosuppressants or corticosteroids
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboplaceboThis group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
InterventionVSL#3This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
Primary Outcome Measures
NameTimeMethod
Changes in cognitionPre and Post the 12 week Intervention

Measures used to assess cognition:

Mini Mental State Exam National Adult Reading Test Free and Cued Selective Reminding Test (FCSRT) Category Fluency Task (Animal Fluency) Colour Trials test 1 \& 2 Sustained Attention Response Task Choice Reaction Time Task Prospective Memory Task Self-Rated Memory Electrophysiological Measures (EEG spectral power - alpha range 8-14Hz)

Secondary Outcome Measures
NameTimeMethod
Changes in MoodPre and Post the 12 week Intervention

Measures used to assess changes in mood:

Centre for Epidemiologic Studies Depression Scale (CES-D) Hospital Anxiety and Depression Scale - Anxiety Scale (HADS-A)

Trial Locations

Locations (1)

Institute of Neuroscience, Trinity College, Dublin

🇮🇪

Dublin, Co. Dublin, Ireland

© Copyright 2025. All Rights Reserved by MedPath